| Budget Amount *help |
¥17,550,000 (Direct Cost: ¥13,500,000、Indirect Cost: ¥4,050,000)
Fiscal Year 2023: ¥4,290,000 (Direct Cost: ¥3,300,000、Indirect Cost: ¥990,000)
Fiscal Year 2022: ¥4,290,000 (Direct Cost: ¥3,300,000、Indirect Cost: ¥990,000)
Fiscal Year 2021: ¥4,290,000 (Direct Cost: ¥3,300,000、Indirect Cost: ¥990,000)
Fiscal Year 2020: ¥4,680,000 (Direct Cost: ¥3,600,000、Indirect Cost: ¥1,080,000)
|
|---|
| Outline of Final Research Achievements |
This study was initiated to build upon the applicant's previous research, aiming to identify candidate molecules for drugs that inhibit pathological angiogenesis involved in the growth and progression of malignant solid tumors, without disrupting physiological angiogenesis. Through multi-omics analysis of human endothelial cells stimulated with vascular endothelial growth factor, KDM2B was identified as a potential target related to epigenome modification. Studies using over-expression and knockdown experimental systems revealed that KDM2B negatively regulates pathological angiogenesis. This research outcome, reported in an international journal, highlights KDM2B as the first epigenomic factor to negatively regulate angiogenesis, marking it as a promising candidate for future drug development.
|
